Jun 25, 2019Marrone Bio receives patent approval on bioinsecticide
Marrone Bio Innovations, a developer of biological crop protection and plant health solutions, has received a notice of allowance from the U.S. Patent and Trademark Office for claims covering the composition and method of manufacturing for Grandevo WDG, an MBI developed microbial-based bioinsecticide.
“We are pleased to have received a notice of allowance on all key claims, notably to the formulation claims surrounding Grandevo WDG,” said Pam Marrone, Founder and CEO of Marrone Bio Innovations. “These allowed claims protect both the composition and method of manufacturing, fortifying our already robust patent position around this exciting bioinsecticide product. We look forward to continued revenue growth of our Grandevo product line, generating long-term value for our shareholders.”
MBI holds more than 400 issued and pending patents and has brought six EPA-registered biological product lines and one biostimulant to market.
Grandevo WDG bioinsecticide/miticide is derived from non-living bacteria that effectively controls a wide variety of chewing and sucking insects and mites, on a wide assortment of crops, from the unique action of multiple compounds through repellency, ingestion and reduction of pest fertility. In an integrated pest management (IPM) program, Grandevo WDG offers multiple modes of action that can significantly benefit producers trying to reduce the risk of pest resistance.
Grandevo WDG can be used on a variety of crops, including potatoes.
Grandevo WDG is exempt from the requirement of tolerances and therefore can be sprayed right up to harvest without creating concerns for exported produce or produce that must meet strict residue requirements of the food marketing chain.
More information on Grandevo WDG is available at marronebio.com.
